Jeil Pharmaceutical Co.,Ltd (271980.KS)
KRW 11640.0
(-5.6%)
KRW 11640.0
(-5.6%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 343.00 KRW | 133.35% |
| 2022 | -1029.79 KRW | -0.39% |
| 2021 | -1025.79 KRW | -316.76% |
| 2020 | 473.24 KRW | 165.61% |
| 2019 | -721.28 KRW | -607.94% |
| 2018 | 142.00 KRW | 94.89% |
| 2017 | 72.86 KRW | -83.53% |
| 2016 | 442.51 KRW | -19.17% |
| 2015 | 547.45 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -1819.49 KRW | -821.26% |
| 2024 Q1 | -197.50 KRW | -28.64% |
| 2023 FY | - KRW | 133.35% |
| 2023 Q3 | -282.14 KRW | -204.65% |
| 2023 Q2 | -92.61 KRW | -110.62% |
| 2023 Q1 | 871.74 KRW | 402.77% |
| 2023 Q4 | -153.53 KRW | 45.58% |
| 2022 Q4 | -287.92 KRW | 4.38% |
| 2022 Q1 | -305.12 KRW | 59.85% |
| 2022 Q2 | -135.56 KRW | 55.57% |
| 2022 FY | - KRW | -0.39% |
| 2022 Q3 | -301.12 KRW | -122.13% |
| 2021 Q4 | -759.95 KRW | -3026.08% |
| 2021 Q2 | 18.00 KRW | 119.99% |
| 2021 Q1 | -90.05 KRW | -577.97% |
| 2021 FY | - KRW | -316.76% |
| 2021 Q3 | -24.31 KRW | -235.06% |
| 2020 Q3 | 29.00 KRW | -82.32% |
| 2020 Q1 | 260.00 KRW | 127.0% |
| 2020 FY | - KRW | 165.61% |
| 2020 Q4 | 18.84 KRW | -35.03% |
| 2020 Q2 | 164.00 KRW | -36.92% |
| 2019 FY | - KRW | -607.94% |
| 2019 Q3 | 75.00 KRW | -42.75% |
| 2019 Q2 | 131.00 KRW | 469.57% |
| 2019 Q1 | 23.00 KRW | -59.03% |
| 2019 Q4 | -963.02 KRW | -1384.03% |
| 2018 Q1 | 23.57 KRW | -3.87% |
| 2018 FY | - KRW | 94.89% |
| 2018 Q4 | 56.14 KRW | 55.94% |
| 2018 Q3 | 36.00 KRW | 176.92% |
| 2018 Q2 | 13.00 KRW | -44.85% |
| 2017 Q2 | 15.00 KRW | 0.0% |
| 2017 Q4 | 24.52 KRW | -26.96% |
| 2017 FY | - KRW | -83.53% |
| 2017 Q3 | 33.57 KRW | 123.8% |
| 2016 FY | - KRW | -19.17% |
| 2015 FY | - KRW | 0.0% |